Unileaflet mitral valve with one single papillary muscle: a rare congenital anomaly characterized by two- and three-dimensional echocardiography.

Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.

BACKGROUND:The appropriate target for systolic blood pressure to reduce cardiovascular risk in older patients with hypertension remains unclear.METHODS:In this multicenter, randomized, controlled trial, we assigned Chinese patients 60 to 80 years of age with hypertension to a systolic blood-pressure target of 110 to less than 130 mm Hg (intensive treatment) or a target of 130 to less than 150 mm Hg (standard treatment). The primary outcome was a composite of stroke, acute coronary syndrome (acute myocardial infarction and hospitalization for unstable angina), acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes.RESULTS:Of the 9624 patients screened for eligibility, 8511 were enrolled in the trial; 4243 were randomly assigned to the intensive-treatment group and 4268 to the standard-treatment group. At 1 year of follow-up, the mean systolic blood pressure was 127.5 mm Hg in the intensive-treatment group and 135.3 mm Hg in the standard-treatment group. During a median follow-up period of 3.34 years, primary-outcome events occurred in 147 patients (3.5%) in the intensive-treatment group, as compared with 196 patients (4.6%) in the standard-treatment group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.92; P = 0.007). The results for most of the individual components of the primary outcome also favored intensive treatment: the hazard ratio for stroke was 0.67 (95% CI, 0.47 to 0.97), acute coronary syndrome 0.67 (95% CI, 0.47 to 0.94), acute decompensated heart failure 0.27 (95% CI, 0.08 to 0.98), coronary revascularization 0.69 (95% CI, 0.40 to 1.18), atrial fibrillation 0.96 (95% CI, 0.55 to 1.68), and death from cardiovascular causes 0.72 (95% CI, 0.39 to 1.32). The results for safety and renal outcomes did not differ significantly between the two groups, except for the incidence of hypotension, which was higher in the intensive-treatment group.CONCLUSIONS:In older patients with hypertension, intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg. (Funded by the Chinese Academy of Medical Sciences and others; STEP ClinicalTrials.gov number, NCT03015311.).

Three-dimensional transesophageal echocardiography measurement of mitral valve area in patients with rheumatic mitral stenosis: multiplanar reconstruction or 3D direct planimetry?

3D direct planimetry is increasingly used in clinical practice as a rapid way to measure the mitral valve area (MVA) in patients with rheumatic mitral stenosis (MS) who underwent three-dimensional transesophageal echocardiography (3D-TEE). However, data on its accuracy and reliability are scarce. This study aimed to compare the MVA measurements obtained by 3D direct planimetry to the conventional technique multiplanar reconstruction (MPR) in MS patients using 3D-TEE. We retrospectively included 49 patients with rheumatic MS undergoing clinically-indicated 3D-TEE in the study. We determined the 3D direct planimetry measurements of MVA from the left atria aspect (MVALA) and the left ventricle aspect (MVALV), and compared those with the MPR method (MVAMPR). We also assessed the major and minor diameters of the mitral valve orifice using MPR and 3D direct planimetry. We found an excellent agreement between the MVA measurements obtained by the MPR method and 3D direct planimetry (MVALA and MVALV) [intraclass correlation coefficients (ICC) = 0.951 and 0.950, respectively]. However, the MVAMPR measurements were significantly larger than the MVALA and MVALV (p < 0.001; mean difference: 0.12 ± 0.15 cm2 and 0.11 ± 0.16 cm2, respectively).The inter-observer and intra-observer variability ICC were 0.875 and 0.856 for MVAMPR, 0.982 and 0.984 for MVALA, and 0.988 and 0.986 for MVALV, respectively. The major diameter measured by MPR (1.90 ± 0.42 cm) was significantly larger than that obtained by 3D direct planimetry (1.72 ± 0.35 cm for the LA aspect, p < 0.001; 1.73 ± 0.36 cm for the LV aspect, p < 0.001). The minor diameter measured by MPR (0.96 ± 0.25 cm) did not differ from that derived by 3D direct planimetry (0.94 ± 0.25 cm for the LA aspect, p = 0.07; 0.95 ± 0.27 cm for the LV aspect, p = 0.32). 3D direct planimetry provides highly reproducible measurements of MVA and yields data in excellent agreement with those obtained by the MPR method. The discrepancy between the two techniques may be due to differences in major diameter measurements of the mitral valve orifice.

Clinical evaluation of five commercially available adult oxygenators in terms of pressure drop during normothermic and hypothermic cardiopulmonary bypass.

BACKGROUND:It is well documented that trans-membrane pressure drop (TMPD) of hollow-fiber membrane oxygenators (HFMO) may lead to hemolysis, damage to platelets, and systemic inflammatory response. The purpose of this study was to evaluate five commercially available adult oxygenators in terms of pressure drop during normothermic and hypothermic cardiopulmonary bypass (CPB).MATERIALS AND METHODS:In a clinical setting, 5 different adult HFMOs were tested in terms of TMPDs. Forty patients scheduled for cardiac surgery were enrolled in the study and were divided into 5 groups according to the type of oxygenator used during CPB: group J (Maquet Quardox n=8), group A (Affinity NT n=8), group P (Polystan Safe Maxi n=8), group T (Terumo Capiox SX 18 n=8) and group C (COBE APEX-TM n=8). Clinical parameters were collected during CPB, including mean arterial pressure (MAP), pump flow, temperature, hematocrit, duration of CPB, cross-clamp time and bypass time. TMPDs of pre-oxygenator and post-oxygenator pressures were recorded at the start of systemic cooling (T1), 10 min after stable hypothermia at 30 degrees C (T2), and at termination of rewarming before the end of CPB (T3).RESULTS:There were no significant differences among the 5 groups in pump-flow rate, temperature, hematocrit, and mean arterial pressure during CPB. TMPDs of group J were the lowest at different time-points (T1, 30.71 +/- 8.42mmHg; T2, 25.71 +/- 5.41 mmHg; T3, 27.42 +/- 13.01 mmHg). Compared to the other 3 groups (P, C and T groups), TMPDs of groups J and A at various time-points were lower (J group compared with the other three groups (p<0.001). Although TMPDs in groups A, P and T during hypothermia were higher than during normothermia and post-rewarming, there was no significant statistical difference (p> 0.05).CONCLUSIONS:These results suggest that the HFMOs in groups J and A produced significantly lower TMPDs and pre- and post-oxygenator extracorporeal circuit pressures during normothermic and hypothermic CPB.

Unileaflet mitral valve with one single papillary muscle: a rare congenital anomaly characterized by two- and three-dimensional echocardiography.

Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.

BACKGROUND:The appropriate target for systolic blood pressure to reduce cardiovascular risk in older patients with hypertension remains unclear.METHODS:In this multicenter, randomized, controlled trial, we assigned Chinese patients 60 to 80 years of age with hypertension to a systolic blood-pressure target of 110 to less than 130 mm Hg (intensive treatment) or a target of 130 to less than 150 mm Hg (standard treatment). The primary outcome was a composite of stroke, acute coronary syndrome (acute myocardial infarction and hospitalization for unstable angina), acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes.RESULTS:Of the 9624 patients screened for eligibility, 8511 were enrolled in the trial; 4243 were randomly assigned to the intensive-treatment group and 4268 to the standard-treatment group. At 1 year of follow-up, the mean systolic blood pressure was 127.5 mm Hg in the intensive-treatment group and 135.3 mm Hg in the standard-treatment group. During a median follow-up period of 3.34 years, primary-outcome events occurred in 147 patients (3.5%) in the intensive-treatment group, as compared with 196 patients (4.6%) in the standard-treatment group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.92; P = 0.007). The results for most of the individual components of the primary outcome also favored intensive treatment: the hazard ratio for stroke was 0.67 (95% CI, 0.47 to 0.97), acute coronary syndrome 0.67 (95% CI, 0.47 to 0.94), acute decompensated heart failure 0.27 (95% CI, 0.08 to 0.98), coronary revascularization 0.69 (95% CI, 0.40 to 1.18), atrial fibrillation 0.96 (95% CI, 0.55 to 1.68), and death from cardiovascular causes 0.72 (95% CI, 0.39 to 1.32). The results for safety and renal outcomes did not differ significantly between the two groups, except for the incidence of hypotension, which was higher in the intensive-treatment group.CONCLUSIONS:In older patients with hypertension, intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg. (Funded by the Chinese Academy of Medical Sciences and others; STEP ClinicalTrials.gov number, NCT03015311.).

Three-dimensional transesophageal echocardiography measurement of mitral valve area in patients with rheumatic mitral stenosis: multiplanar reconstruction or 3D direct planimetry?

3D direct planimetry is increasingly used in clinical practice as a rapid way to measure the mitral valve area (MVA) in patients with rheumatic mitral stenosis (MS) who underwent three-dimensional transesophageal echocardiography (3D-TEE). However, data on its accuracy and reliability are scarce. This study aimed to compare the MVA measurements obtained by 3D direct planimetry to the conventional technique multiplanar reconstruction (MPR) in MS patients using 3D-TEE. We retrospectively included 49 patients with rheumatic MS undergoing clinically-indicated 3D-TEE in the study. We determined the 3D direct planimetry measurements of MVA from the left atria aspect (MVALA) and the left ventricle aspect (MVALV), and compared those with the MPR method (MVAMPR). We also assessed the major and minor diameters of the mitral valve orifice using MPR and 3D direct planimetry. We found an excellent agreement between the MVA measurements obtained by the MPR method and 3D direct planimetry (MVALA and MVALV) [intraclass correlation coefficients (ICC) = 0.951 and 0.950, respectively]. However, the MVAMPR measurements were significantly larger than the MVALA and MVALV (p < 0.001; mean difference: 0.12 ± 0.15 cm2 and 0.11 ± 0.16 cm2, respectively).The inter-observer and intra-observer variability ICC were 0.875 and 0.856 for MVAMPR, 0.982 and 0.984 for MVALA, and 0.988 and 0.986 for MVALV, respectively. The major diameter measured by MPR (1.90 ± 0.42 cm) was significantly larger than that obtained by 3D direct planimetry (1.72 ± 0.35 cm for the LA aspect, p < 0.001; 1.73 ± 0.36 cm for the LV aspect, p < 0.001). The minor diameter measured by MPR (0.96 ± 0.25 cm) did not differ from that derived by 3D direct planimetry (0.94 ± 0.25 cm for the LA aspect, p = 0.07; 0.95 ± 0.27 cm for the LV aspect, p = 0.32). 3D direct planimetry provides highly reproducible measurements of MVA and yields data in excellent agreement with those obtained by the MPR method. The discrepancy between the two techniques may be due to differences in major diameter measurements of the mitral valve orifice.

Clinical evaluation of five commercially available adult oxygenators in terms of pressure drop during normothermic and hypothermic cardiopulmonary bypass.

BACKGROUND:It is well documented that trans-membrane pressure drop (TMPD) of hollow-fiber membrane oxygenators (HFMO) may lead to hemolysis, damage to platelets, and systemic inflammatory response. The purpose of this study was to evaluate five commercially available adult oxygenators in terms of pressure drop during normothermic and hypothermic cardiopulmonary bypass (CPB).MATERIALS AND METHODS:In a clinical setting, 5 different adult HFMOs were tested in terms of TMPDs. Forty patients scheduled for cardiac surgery were enrolled in the study and were divided into 5 groups according to the type of oxygenator used during CPB: group J (Maquet Quardox n=8), group A (Affinity NT n=8), group P (Polystan Safe Maxi n=8), group T (Terumo Capiox SX 18 n=8) and group C (COBE APEX-TM n=8). Clinical parameters were collected during CPB, including mean arterial pressure (MAP), pump flow, temperature, hematocrit, duration of CPB, cross-clamp time and bypass time. TMPDs of pre-oxygenator and post-oxygenator pressures were recorded at the start of systemic cooling (T1), 10 min after stable hypothermia at 30 degrees C (T2), and at termination of rewarming before the end of CPB (T3).RESULTS:There were no significant differences among the 5 groups in pump-flow rate, temperature, hematocrit, and mean arterial pressure during CPB. TMPDs of group J were the lowest at different time-points (T1, 30.71 +/- 8.42mmHg; T2, 25.71 +/- 5.41 mmHg; T3, 27.42 +/- 13.01 mmHg). Compared to the other 3 groups (P, C and T groups), TMPDs of groups J and A at various time-points were lower (J group compared with the other three groups (p<0.001). Although TMPDs in groups A, P and T during hypothermia were higher than during normothermia and post-rewarming, there was no significant statistical difference (p> 0.05).CONCLUSIONS:These results suggest that the HFMOs in groups J and A produced significantly lower TMPDs and pre- and post-oxygenator extracorporeal circuit pressures during normothermic and hypothermic CPB.